Abstract | AIM: PATIENTS & METHODS: RESULTS: Differences in prophylaxis intensity and day of initiation relative to guideline recommendations were observed. In hematology patients, higher rates of CIN and FN occurred at cycle level, and rate of FN was higher at patient level (9.1 vs 5.0% in solid tumor patients). CONCLUSION: Adequate GCSF support in hematology and solid tumor patients is important to prevent CIN/FN and related hospitalizations and chemotherapy disturbances.
|
Authors | Heinz Ludwig, Carsten Bokemeyer, Matti Aapro, Mario Boccadoro, Pere Gascón, Kris Denhaerynck, Andriy Krendyukov, Ivo Abraham, Karen MacDonald |
Journal | Future oncology (London, England)
(Future Oncol)
Vol. 15
Issue 8
Pg. 897-907
(Mar 2019)
ISSN: 1744-8301 [Electronic] England |
PMID | 30827127
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Observational Study)
|
Chemical References |
- Antineoplastic Agents
- Biosimilar Pharmaceuticals
- Hematologic Agents
- Filgrastim
|
Topics |
- Aged
- Antineoplastic Agents
(adverse effects)
- Biosimilar Pharmaceuticals
(administration & dosage, adverse effects)
- Chemotherapy-Induced Febrile Neutropenia
(etiology, prevention & control)
- Female
- Filgrastim
(administration & dosage, adverse effects)
- Hematologic Agents
(administration & dosage, adverse effects)
- Humans
- Male
- Middle Aged
- Neoplasms
(drug therapy)
- Prospective Studies
- Treatment Outcome
|